Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a commercial presence in Europe and a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate, which is currently being studied in a Phase 3 program for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington, with offices in London and Milan under the name CTI Life Sciences Limited. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$0.27 - 0.23 (46.00%)
Day High:$0.31
Day Low:$0.26
Volume:7,375,419
02/10/169:40 a.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345
invest@ctibiopharma.com


 

Recent News

MORE
DateTitle 
Feb 09, 2016CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S.
SEATTLE, Feb. 9, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today provided an update regarding the clinical studies being conducted under the Company's Investigational New Drug ("IND") application for pacritinib. Following the issuance of the Company's February 8, 2016, press release describing the partial clinical hold issued by the U.S. Food and Drug Administration (FDA) regarding those clinical studies, the Company received an oral communication from the F... 
Printer Friendly Version
Feb 08, 2016CTI BioPharma Provides Update On Investigational Agent Pacritinib
FDA Places Partial Clinical Hold on Pacritinib IND; Currently Enrolled Patients Benefiting from Pacritinib Can Continue Receiving Pacritinib Phase 3 Clinical Trial (PERSIST-2) Evaluating Pacritinib for Patients with Myelofibrosis and Platelet Counts of ≤100,000/μL has Completed Enrollment SEATTLE, Feb. 8, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced that the Company received written communication from the U.S. Food and Drug Administration... 
Printer Friendly Version
Jan 13, 2016CTI BioPharma Appoints Matthew Perry To Board Of Directors
SEATTLE, Jan. 13, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Matthew Perry, President of BVF Partners L.P. (BVF Partners) and CTI BioPharma's largest shareholder, has been appointed to the Board of Directors of CTI BioPharma. "We are pleased to welcome Matthew Perry from BVF Partners, our largest shareholder, onto our Board at this exciting stage of our company's evolution," commented James A. Bianco, M.D., CTI BioPharma's President a... 
Printer Friendly Version

Events

MORE
DateTitle
Dec 02, 2015
CTI BioPharma Corp at 27th Annual Piper Jaffray Healthcare Conference
Nov 05, 2015
Q3 2015 CTI BioPharma Corp Earnings Conference Call
Data provided by Nasdaq. Minimum 15 minutes delayed.